|
Secondary malignant neoplasm of lymph node
|
0.100 |
Biomarker
|
disease |
BEFREE |
Highly sensitive detection of sentinel lymph node metastasis of breast cancer by digital PCR for RASSF1A methylation.
|
31638213 |
2019 |
|
Secondary malignant neoplasm of lymph node
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
RASSF1A promoter methylation was associated with tumor grade (grade 3-4 vs 1-2: OR 2.31, 95% CI 1.12-4.77, P = 0.023), lymph node metastasis (yes vs no: OR 2.97, 95% CI 1.60-5.52, P = 0.001), tumor histology (squamous cell carcinoma vs adenocarcinoma: OR 0.49, 95% CI 0.22-1.08, P = 0.076), and HPV infection (positive vs negative: OR 0.45, 95% CI 0.28-0.73, P = 0.001).
|
29288321 |
2018 |
|
Secondary malignant neoplasm of lymph node
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The low expression of RASSF1A and SIRT6 and lymph node metastasis were the risk factors affecting the prognosis of NSCLC patients.
|
29204192 |
2017 |
|
Secondary malignant neoplasm of lymph node
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Further subgroup analysis by ethnicity demonstrated that RASSF1A promoter methylation was correlated with clinicopathological characteristics of CRC patients among Asians (clinical stage: OR = 2.55, 95% CI 1.55-4.20, P < 0.001; histological grade: OR = 2.70, 95% CI 1.44-5.06, P = 0.002; lymph node metastasis: OR = 4.09, 95% CI 1.49-11.26, P = 0.006; distant metastasis: OR = 5.38, 95% CI 1.73-16.70, P = 0.004), but not among Caucasians and Africans (all P > 0.05).
|
24566684 |
2014 |
|
Secondary malignant neoplasm of lymph node
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Both frequency and extent of RASSF1A and RBSP3 mRNA level decrease were more pronounced in tumors with lymph node metastases compared with non-metastatic ones (p ≤ 0.05).
|
23478628 |
2013 |
|
Secondary malignant neoplasm of lymph node
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, we report that compared with melanocytes in normal skins or benign skin lesions, RASSF1A is down-regulated in melanoma tissues as well as cell lines, and its expression negatively correlates with lymph node metastasis.
|
21660959 |
2011 |
|
Secondary malignant neoplasm of lymph node
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Taken together, our results demonstrate that silencing of RASSF1A and RARbeta2 expression by promoter hypermethylation is associated with highly differentiated tumors, advanced tumor stage and the presence of lymph node metastasis.
|
19221469 |
2009 |
|
Secondary malignant neoplasm of lymph node
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
However, the promoter methylation of the RASSF1A gene in breast cancers were not correlated with clinical parameters, such as ages, histological types, TNM stages and lymph node metastases.
|
18425370 |
2008 |
|
Secondary malignant neoplasm of lymph node
|
0.100 |
Biomarker
|
disease |
BEFREE |
Down-regulated expression of RASSF1A showed a significant association with WHO grade, tumor status, and lymph node metastasis, showing its possible utility as a biomarker for clinical specimens.
|
17720308 |
2007 |
|
Secondary malignant neoplasm of lymph node
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
RASSF1A methylation was associated with histopathologic type of tumors (P = 0.03) and lymph node metastasis (P = 0.004), and p16 methylation with older patient age (P = 0.002) and liver metastasis (P = 0.04).
|
16258509 |
2005 |